Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia.
Bromodeoxyuridine (BrdU) was administered to 86 newly diagnosed patients with standard risk acute myeloid leukemia (AML) prior to starting induction therapy and the labeling index (LI), durations of S-phase (Ts), and the cell cycle (Tc) of myeloblasts were determined. Induction therapy with cytosine arabinoside and daunomycin was subsequently started. Bone marrow biopsies were obtained on days 6 and 17 and weekly thereafter, and were treated with a monoclonal anti-BrdU antibody to determine the fate of cells labeled on day 0 by BrdU. BrdU labeled granulocytes indicating the presence of in vivo differentiation (Diff+) were identified in 48 patients ranging from 1+ (1-10 labeled cells) to 4+ (greater than 31 labeled granulocytes). When compared to 38 differentiation negative (Diff-) patients, Diff+ group had longer Ts (14.5 hr vs. 10.95 hr, P = 0.015) and Tc (59.7 hr vs. 41.7 hr, P = 0.017). Remission duration was significantly longer (no median) for 3-4+ Diff+ as compared to Diff- (median = 220 days) patients (Wilcoxon P = 0.04). We conclude that the detection of in vivo differentiation in AML patients indicates a favorable long-term prognosis either due to the presence of a substantial amount of normal residual hematopoiesis prior to starting induction therapy or due to the ability of leukemic cells to undergo differentiation.
Raza
A
A
Roswell Park Memorial Institute, Buffalo, New York.
Preisler
H
H
Lampkin
B
B
Lykins
J
J
Kukla
C
C
Gartside
P
P
Sheikh
Y
Y
Yousuf
N
N
White
M
M
Barcos
M
M
D000208:Acute Disease; D000911:Antibodies, Monoclonal; D001707:Biopsy, Needle; D001853:Bone Marrow / Q000473:pathology; D001973:Bromodeoxyuridine; D002453:Cell Cycle; D002454:Cell Differentiation; D002455:Cell Division; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006098:Granulocytes / Q000473:pathology; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000473:pathology*; D011379:Prognosis; D012074:Remission Induction; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D003561:Cytarabine; D001973:Bromodeoxyuridine; D003630:Daunorubicin